Bishal Gyawali, Associate Professor at Queen’s University, shared on LinkedIn:

“Have you read our new paper in BMJ Oncology?
In this paper, we study the validity of DFS as a surrogate endpoint for OS in (Neo) adjuvant pancreatic cancer trials. An important project led by the brilliant Luis Felipe Leite da Silva, a medical student from Brazil.”

Title: Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis

Authors: Luís Felipe Leite, Luiz F Costa de Almeida, Lucas Diniz da Conceição, Mariana Macambira Noronha, Marcos Belotto, Erick F Saldanha, Thais Baccili Cury Megid, Renata D’Alpino Peixoto, Bishal Gyawali

Read the Full Article in BMJ Oncology.

Bishal Gyawali

Bishal Gyawali: The validity of DFS as a surrogate endpoint for OS in pancreatic cancer trials

“Have you read our new paper in BMJ Oncology?
In this paper, we study the validity of DFS as a surrogate endpoint for OS in (Neo) adjuvant pancreatic cancer trials. An important project led by the brilliant Luis Felipe Leite da Silva, a medical student from Brazil.”

Bishal Gyawali: The validity of DFS as a surrogate endpoint for OS in pancreatic cancer trials

“Have you read our new paper in BMJ Oncology? In this paper, we study the validity of DFS as a surrogate endpoint for OS in (Neo) adjuvant pancreatic cancer trials. An important project led by the brilliant Luis Felipe Leite da Silva, a medical student from Brazil.”

“Have you read our new paper in BMJ Oncology?
In this paper, we study the validity of DFS as a surrogate endpoint for OS in (Neo) adjuvant pancreatic cancer trials. An important project led by the brilliant Luis Felipe Leite da Silva, a medical student from Brazil.”